Пресс-релиз компании «Ф. Хоффманн-Ля Рош»

Читать статью в PDFpdficon


  1. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–10. doi:10.1056/nejmoa1313984.
  2. Lamanna N, et al. Chronic Lymphocytic Leukemia and Hairy-Cell Leukemia. Cancer Management. Available from: http://www.cancernetwork.com/cancer-management/chronic-lymphocytic-leukemia-and-hairy-cell-leukemia.
  3. Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–403. doi: 10.1016/j.ejca.2012.12.027.
  4. GLOBOCAN Europe (2012). Estimate cancer incidence, all ages: both sexes. Available from: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute.
  5. GLOBOCAN Europe (2012). Estimate cancer mortality, all ages: both sexes. Available from: http://globocan.iarc.fr/old/summary_table_pop-html.asp?selection=62968&title=Europe&sex=0&type=1&window=1&sort=0&submit =%C2%A0Execute.
  6. Goede V, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015:1–3. doi: 10.1038/leu.2015.14.